Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we compared the trading price of each holding against the average analyst 12-month forward target price. From this, we computed the weighted average implied analyst target price for the ETF itself.
For the Dimensional U.S. Equity Market ETF (Symbol: DFUS), we found that the implied analyst target price based on its underlying holdings is $80.80 per unit. With DFUS trading at a recent price near $72.40 per unit, this suggests that analysts see an 11.60% upside for this ETF by looking through to the average analyst targets of its underlying holdings.
Three of DFUS’s underlying holdings stand out with notable upside potential to their analyst target prices:
– **Iovance Biotherapeutics Inc (Symbol: IOVA)**
IOVA has recently traded at $2.24 per share, while the average analyst target price is $9.10 per share—representing a potential upside of 306.25%.
– **Dianthus Therapeutics Inc (Symbol: DNTH)**
DNTH’s recent share price is $36.20, with an average analyst target of $62.73 per share. This indicates a potential upside of 73.28%.
– **Orion SA (Symbol: OEC)**
OEC is currently trading at $6.21 per share. Analysts expect it to reach a target price of $10.50 per share, which is 69.08% above the recent price.
Below is a summary table outlining the current analyst target prices for these stocks:
| Name | Symbol | Recent Price | Avg. Analyst 12-Mo. Target | % Upside to Target |
|————————————|——–|————–|—————————-|——————–|
| Dimensional U.S. Equity Market ETF | DFUS | $72.40 | $80.80 | 11.60% |
| Iovance Biotherapeutics Inc | IOVA | $2.24 | $9.10 | 306.25% |
| Dianthus Therapeutics Inc | DNTH | $36.20 | $62.73 | 73.28% |
| Orion SA | OEC | $6.21 | $10.50 | 69.08% |
*Note: A twelve-month price history chart comparing the stock performance of IOVA, DNTH, and OEC is available below.*
—
**Are Analysts’ Targets Justified?**
Are analysts justified in these targets, or could they be overly optimistic about where these stocks will trade 12 months from now? Do the analysts have a valid basis for their targets, or might they be behind the curve on recent company and industry developments?
A high price target relative to a stock’s current trading price can reflect optimism about the future. However, it can also be a precursor to target price downgrades if the targets were set based on outdated information.
These questions highlight the importance of conducting further research before making investment decisions.
—
**Related Content:**
– 10 ETFs With Most Upside To Analyst Targets
– CVI Price Target
– Top Ten Hedge Funds Holding ERJ
– AX Market Cap History
—
*Disclaimer: The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.*
https://www.nasdaq.com/articles/how-pieces-add-dfus-headed-81
Be First to Comment